Myriad Prepared to Make Small IP Sacrifice to Aussies in Light of Landmark US Patent Case
Myriad Prepared to Make Small IP Sacrifice to Aussies in Light of Landmark US Patent Case
In deciding to surrender a key patent No. 686004, which covers certain BRCA1 mutations to the Australian government, it seems Myriad may be preparing to sacrifice a small slice of its IP holdings in a secondary market in order to avoid any erosion of its position in the landmark US case challenging seven of its BRCA gene patents.